Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

That's far above the 82 million Americans currently eligible for today's most-prescribed drug, cholesterol-lowering statins .

In a study by the Northwestern Medicine Canning Thoracic Institute in Chicago, the RNA in the SARS-CoV-2 virus was found to "trigger the development of a unique type of immune cell with anti-cancer ...

Healthcare executives and investors expect an uptick in initial public offerings and corporate dealmaking in 2025, with geopolitical tensions overtaking funding challenges as the biggest risk to the ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

The United States must address the growing public health crisis over high traffic deaths that remain significantly above ...

A Vitamin B supplement has been recalled due to being incorrectly formulated with niacin rather than niacinamide.

Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...